Editas Medicine, Inc. (NASDAQ:EDIT) Stock Position Lifted by Barclays PLC

Barclays PLC boosted its stake in Editas Medicine, Inc. (NASDAQ:EDIT) by 46.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 178,507 shares of the company’s stock after buying an additional 56,986 shares during the quarter. Barclays PLC owned approximately 0.22% of Editas Medicine worth $607,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. Millennium Management LLC raised its holdings in shares of Editas Medicine by 10.0% during the second quarter. Millennium Management LLC now owns 2,459,629 shares of the company’s stock worth $11,486,000 after acquiring an additional 223,012 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its stake in shares of Editas Medicine by 133.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 529,834 shares of the company’s stock worth $1,807,000 after purchasing an additional 302,652 shares in the last quarter. Integral Health Asset Management LLC lifted its holdings in shares of Editas Medicine by 50.0% during the 2nd quarter. Integral Health Asset Management LLC now owns 675,000 shares of the company’s stock valued at $3,152,000 after buying an additional 225,000 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Editas Medicine by 37.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 54,787 shares of the company’s stock valued at $187,000 after buying an additional 14,888 shares in the last quarter. Finally, FMR LLC increased its holdings in Editas Medicine by 110.7% in the third quarter. FMR LLC now owns 203,087 shares of the company’s stock worth $693,000 after buying an additional 106,684 shares during the last quarter. Institutional investors and hedge funds own 71.90% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on EDIT. Robert W. Baird reduced their target price on shares of Editas Medicine from $10.00 to $8.00 and set an “outperform” rating for the company in a research note on Friday, December 13th. JPMorgan Chase & Co. cut shares of Editas Medicine from a “neutral” rating to an “underweight” rating in a report on Monday, December 16th. Bank of America lowered Editas Medicine from a “buy” rating to an “underperform” rating and cut their target price for the company from $13.00 to $1.00 in a report on Monday, November 25th. Barclays decreased their price target on Editas Medicine from $5.00 to $3.00 and set an “equal weight” rating for the company in a research note on Friday, December 13th. Finally, Royal Bank of Canada cut their price objective on Editas Medicine from $5.00 to $4.00 and set a “sector perform” rating on the stock in a research note on Friday, December 13th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $7.00.

Editas Medicine Price Performance

NASDAQ:EDIT opened at $1.24 on Friday. Editas Medicine, Inc. has a one year low of $1.12 and a one year high of $11.58. The company has a fifty day moving average price of $1.85 and a 200 day moving average price of $3.26. The stock has a market cap of $102.36 million, a P/E ratio of -0.48 and a beta of 1.95.

Editas Medicine (NASDAQ:EDIT) last released its earnings results on Monday, November 4th. The company reported ($0.75) earnings per share for the quarter, meeting the consensus estimate of ($0.75). Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%. The business had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $3.93 million. During the same quarter last year, the company earned ($0.55) earnings per share. The firm’s revenue was down 98.9% on a year-over-year basis. As a group, equities research analysts anticipate that Editas Medicine, Inc. will post -2.64 EPS for the current year.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.